Bamlanivimab-plus-Etesevimab-Distribution-Fact-Sheet Bamlanivimab/Etesevimab Distribution Fact Sheet

​​​This information is no longer accurate and is for historical purposes only. For the latest on COVID-19 treatment, please visit the COVID-19 Treatments page

Bamlanivimab/Etesevimab Distribution Fact Sheet


With the rapid spread of the Omicron variant in mid-December 2021 and data showing that bamlanivimab/etesevimab is not effective in patients infected with this variant, the NIH updated their treatment guidelines to recommend against the use of bamlanivimab/etesevimab on January 19, 2022.

On January 24, 2022, the FDA revised the EUA for bamlanivimab/etesevimab to limit its use. Bamlanivimab/etesevimab is not authorized for use in any U.S. states, territories, and jurisdictions at this time.

HHS has paused allocation of bamlanivimab/etesevimab, and, at this time, CDPH is not distributing bamlanivimab/etesevimab to jursidictions. This product is not available and cannot be ordered.

If future variants are found to be susceptible to bamlanivimab/etesevimab, this product may become available in the future.

​Originally published on March 9, 2021